The apolipoprotein testing market size has grown strongly in recent years. It will grow from $3.11 billion in 2025 to $3.29 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, wider adoption of lipid testing protocols, expansion of diagnostic laboratory networks, growing awareness of preventive healthcare, availability of standardized apolipoprotein assays.
The apolipoprotein testing market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing demand for precision cardiovascular diagnostics, rising integration of molecular diagnostics in routine testing, expansion of personalized medicine approaches, growing investments in automated diagnostic technologies, increasing focus on early disease risk stratification. Major trends in the forecast period include increasing adoption of advanced lipid risk assessment tests, rising demand for preventive cardiovascular diagnostics, growing integration of genetic and protein testing, expansion of automated immunoassay platforms, enhanced focus on personalized cardiac risk profiling.
The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the apolipoprotein testing market in the coming years. Cardiovascular disease (CVD) includes a range of conditions that affect the heart and blood vessels, leading to outcomes such as heart attacks, strokes, and peripheral vascular disease. The incidence of cardiovascular disorders is increasing due to factors including unhealthy dietary patterns, growing obesity levels, and aging populations. Apolipoproteins, such as ApoA-I and ApoB, play a critical role in lipid transport within the bloodstream. Measuring their levels supports the assessment of cardiovascular risk and helps customize lipid-lowering therapies for effective disease management. For example, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4 percent rise from the previous year’s rate of 224.4 per 100,000, following a 4.6 percent increase in 2023 and marking the first rise observed in several years. Therefore, the growing prevalence of cardiovascular diseases is contributing to the expansion of the apolipoprotein testing market.
Leading companies operating in the apolipoprotein testing market are launching enhanced heart health plans to deliver more comprehensive assessments and personalized guidance for cholesterol management and cardiovascular risk reduction. These advanced heart health plans are upgraded wellness programs that provide detailed evaluations and customized recommendations to improve overall cardiovascular health. For instance, in January 2023, InsideTracker, a US-based personal health analysis company, expanded its Ultimate Plan to include Apolipoprotein B (ApoB) testing, a key marker of heart health. This addition allows users to gain a deeper understanding of their cardiovascular condition, as elevated ApoB levels are linked to a higher risk of atherosclerosis and heart disease. The plan provides users with insights into their ApoB levels relative to standard benchmarks, along with personalized lifestyle recommendations based on extensive scientific research conducted by InsideTracker’s science team.
In December 2023, Danaher Corporation, a US-based life sciences and diagnostics innovator, acquired Abcam Limited for an undisclosed amount. Through this acquisition, Danaher intends to leverage Abcam’s advanced technologies and strong market position to support growth within its life sciences portfolio. The transaction is expected to improve disease mapping capabilities and accelerate drug discovery efforts. Abcam Limited is a UK-based biotechnology company that offers products such as the Apolipoprotein AI (APOA1) human in vitro ELISA kit.
Major companies operating in the apolipoprotein testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Mayo Clinic Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Bio-Rad Laboratories Inc., Randox Laboratories Ltd., R&D Systems Inc., Elabscience Bionovation Inc., Sekisui Diagnostics LLC, RayBiotech Inc., Mabtech AB, Bioss Inc., Aviva Systems Biology Corporation, Abnova Corporation, DiaSys Diagnostic Systems GmbH, Enzo Life Sciences Inc., Eagle Biosciences Inc., CLOUD-CLONE CORP., ELK Biotechnology CO. Ltd., LifeSpan BioSciences Inc.,
North America was the largest region in the apolipoprotein testing market in 2025. The regions covered in the apolipoprotein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the apolipoprotein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the apolipoprotein testing market by increasing costs of imported diagnostic instruments, assay kits, reagents, automation systems, and laboratory consumables. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported testing platforms, while Asia-Pacific faces higher costs for advanced diagnostic equipment adoption. These tariffs are raising testing costs and influencing procurement decisions. At the same time, they are encouraging domestic production of diagnostic kits, regional laboratory automation development, and local innovation in cardiovascular testing solutions.
The apolipoprotein testing market research report is one of a series of new reports that provides apolipoprotein testing market statistics, including apolipoprotein testing industry global market size, regional shares, competitors with a apolipoprotein testing market share, detailed apolipoprotein testing market segments, market trends and opportunities, and any further data you may need to thrive in the apolipoprotein testing industry. This apolipoprotein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Apolipoprotein testing involves measuring the levels of specific apolipoproteins in the blood to evaluate cardiovascular risk and lipid metabolism. This testing is used to determine an individual’s likelihood of developing cardiovascular diseases by assessing key proteins that play a role in lipid transport and metabolism.
The primary apolipoproteins analyzed in apolipoprotein testing include apolipoprotein A-I, apolipoprotein B, and apolipoprotein E. Apolipoprotein A-I is a protein that plays an essential role in lipid metabolism and is mainly found in high-density lipoprotein (HDL), where it helps remove excess cholesterol from the bloodstream, thereby lowering the risk of heart disease. Apolipoprotein testing employs various technologies such as immunoassays and polymerase chain reaction (PCR) across multiple applications, including cardiovascular disease risk assessment, genetic testing, and others. These tests are utilized by a range of end users, including hospitals and clinics, diagnostic laboratories, and research and academic institutes.
The apolipoprotein testing market consists of revenues earned by entities by providing services such as monitoring lipid disorders, evaluating treatment effectiveness, and early detection of metabolic syndrome. The market value includes the value of related goods sold by the service provider or included within the service offering. The apolipoprotein testing market also includes sales of spectrophotometers, ELISA plate readers, and centrifuges. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The apolipoprotein testing market size is expected to see strong growth in the next few years. It will grow to $4.09 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing demand for precision cardiovascular diagnostics, rising integration of molecular diagnostics in routine testing, expansion of personalized medicine approaches, growing investments in automated diagnostic technologies, increasing focus on early disease risk stratification. Major trends in the forecast period include increasing adoption of advanced lipid risk assessment tests, rising demand for preventive cardiovascular diagnostics, growing integration of genetic and protein testing, expansion of automated immunoassay platforms, enhanced focus on personalized cardiac risk profiling.
The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the apolipoprotein testing market in the coming years. Cardiovascular disease (CVD) includes a range of conditions that affect the heart and blood vessels, leading to outcomes such as heart attacks, strokes, and peripheral vascular disease. The incidence of cardiovascular disorders is increasing due to factors including unhealthy dietary patterns, growing obesity levels, and aging populations. Apolipoproteins, such as ApoA-I and ApoB, play a critical role in lipid transport within the bloodstream. Measuring their levels supports the assessment of cardiovascular risk and helps customize lipid-lowering therapies for effective disease management. For example, in January 2024, according to the American Heart Association, a US-based nonprofit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000, representing a 4 percent rise from the previous year’s rate of 224.4 per 100,000, following a 4.6 percent increase in 2023 and marking the first rise observed in several years. Therefore, the growing prevalence of cardiovascular diseases is contributing to the expansion of the apolipoprotein testing market.
Leading companies operating in the apolipoprotein testing market are launching enhanced heart health plans to deliver more comprehensive assessments and personalized guidance for cholesterol management and cardiovascular risk reduction. These advanced heart health plans are upgraded wellness programs that provide detailed evaluations and customized recommendations to improve overall cardiovascular health. For instance, in January 2023, InsideTracker, a US-based personal health analysis company, expanded its Ultimate Plan to include Apolipoprotein B (ApoB) testing, a key marker of heart health. This addition allows users to gain a deeper understanding of their cardiovascular condition, as elevated ApoB levels are linked to a higher risk of atherosclerosis and heart disease. The plan provides users with insights into their ApoB levels relative to standard benchmarks, along with personalized lifestyle recommendations based on extensive scientific research conducted by InsideTracker’s science team.
In December 2023, Danaher Corporation, a US-based life sciences and diagnostics innovator, acquired Abcam Limited for an undisclosed amount. Through this acquisition, Danaher intends to leverage Abcam’s advanced technologies and strong market position to support growth within its life sciences portfolio. The transaction is expected to improve disease mapping capabilities and accelerate drug discovery efforts. Abcam Limited is a UK-based biotechnology company that offers products such as the Apolipoprotein AI (APOA1) human in vitro ELISA kit.
Major companies operating in the apolipoprotein testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Mayo Clinic Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Bio-Rad Laboratories Inc., Randox Laboratories Ltd., R&D Systems Inc., Elabscience Bionovation Inc., Sekisui Diagnostics LLC, RayBiotech Inc., Mabtech AB, Bioss Inc., Aviva Systems Biology Corporation, Abnova Corporation, DiaSys Diagnostic Systems GmbH, Enzo Life Sciences Inc., Eagle Biosciences Inc., CLOUD-CLONE CORP., ELK Biotechnology CO. Ltd., LifeSpan BioSciences Inc.,
North America was the largest region in the apolipoprotein testing market in 2025. The regions covered in the apolipoprotein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the apolipoprotein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the apolipoprotein testing market by increasing costs of imported diagnostic instruments, assay kits, reagents, automation systems, and laboratory consumables. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported testing platforms, while Asia-Pacific faces higher costs for advanced diagnostic equipment adoption. These tariffs are raising testing costs and influencing procurement decisions. At the same time, they are encouraging domestic production of diagnostic kits, regional laboratory automation development, and local innovation in cardiovascular testing solutions.
The apolipoprotein testing market research report is one of a series of new reports that provides apolipoprotein testing market statistics, including apolipoprotein testing industry global market size, regional shares, competitors with a apolipoprotein testing market share, detailed apolipoprotein testing market segments, market trends and opportunities, and any further data you may need to thrive in the apolipoprotein testing industry. This apolipoprotein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Apolipoprotein testing involves measuring the levels of specific apolipoproteins in the blood to evaluate cardiovascular risk and lipid metabolism. This testing is used to determine an individual’s likelihood of developing cardiovascular diseases by assessing key proteins that play a role in lipid transport and metabolism.
The primary apolipoproteins analyzed in apolipoprotein testing include apolipoprotein A-I, apolipoprotein B, and apolipoprotein E. Apolipoprotein A-I is a protein that plays an essential role in lipid metabolism and is mainly found in high-density lipoprotein (HDL), where it helps remove excess cholesterol from the bloodstream, thereby lowering the risk of heart disease. Apolipoprotein testing employs various technologies such as immunoassays and polymerase chain reaction (PCR) across multiple applications, including cardiovascular disease risk assessment, genetic testing, and others. These tests are utilized by a range of end users, including hospitals and clinics, diagnostic laboratories, and research and academic institutes.
The apolipoprotein testing market consists of revenues earned by entities by providing services such as monitoring lipid disorders, evaluating treatment effectiveness, and early detection of metabolic syndrome. The market value includes the value of related goods sold by the service provider or included within the service offering. The apolipoprotein testing market also includes sales of spectrophotometers, ELISA plate readers, and centrifuges. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Apolipoprotein Testing Market Characteristics
3. Apolipoprotein Testing Market Supply Chain Analysis
4. Global Apolipoprotein Testing Market Trends and Strategies
5. Apolipoprotein Testing Market Analysis of End Use Industries
7. Global Apolipoprotein Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Apolipoprotein Testing Total Addressable Market (TAM) Analysis for the Market
9. Apolipoprotein Testing Market Segmentation
10. Apolipoprotein Testing Market Regional and Country Analysis
11. Asia-Pacific Apolipoprotein Testing Market
12. China Apolipoprotein Testing Market
13. India Apolipoprotein Testing Market
14. Japan Apolipoprotein Testing Market
15. Australia Apolipoprotein Testing Market
16. Indonesia Apolipoprotein Testing Market
17. South Korea Apolipoprotein Testing Market
18. Taiwan Apolipoprotein Testing Market
19. South East Asia Apolipoprotein Testing Market
20. Western Europe Apolipoprotein Testing Market
21. UK Apolipoprotein Testing Market
22. Germany Apolipoprotein Testing Market
23. France Apolipoprotein Testing Market
24. Italy Apolipoprotein Testing Market
25. Spain Apolipoprotein Testing Market
26. Eastern Europe Apolipoprotein Testing Market
27. Russia Apolipoprotein Testing Market
28. North America Apolipoprotein Testing Market
29. USA Apolipoprotein Testing Market
30. Canada Apolipoprotein Testing Market
31. South America Apolipoprotein Testing Market
32. Brazil Apolipoprotein Testing Market
33. Middle East Apolipoprotein Testing Market
34. Africa Apolipoprotein Testing Market
36. Apolipoprotein Testing Market Competitive Landscape and Company Profiles
37. Apolipoprotein Testing Market Other Major and Innovative Companies
40. Apolipoprotein Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Apolipoprotein Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses apolipoprotein testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for apolipoprotein testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The apolipoprotein testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Apolipoprotein: Apolipoprotein A-I; Apolipoprotein B; Apolipoprotein E2) By Technology: Immunoassays; Polymerase Chain Reaction (PCR)
3) By Application: Cardiovascular Disease Risk Assessment; Genetic Testing; Other Applications
4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Research And Academic Institutes
Subsegments:
1) By Apolipoprotein A-I: Quantitative Testing; Qualitative Testing; Functional Testing2) By Apolipoprotein B: Total Apolipoprotein B Testing; Apolipoprotein B100 Testing; Apolipoprotein B48 Testing
3) By Apolipoprotein E: Genotyping Tests; Protein Level Testing; Functional Assays
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Mayo Clinic Laboratories; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Bio-Rad Laboratories Inc.; Randox Laboratories Ltd.; R&D Systems Inc.; Elabscience Bionovation Inc.; Sekisui Diagnostics LLC; RayBiotech Inc.; Mabtech AB; Bioss Inc.; Aviva Systems Biology Corporation; Abnova Corporation; DiaSys Diagnostic Systems GmbH; Enzo Life Sciences Inc.; Eagle Biosciences Inc.; CLOUD-CLONE CORP.; ELK Biotechnology CO. Ltd.; LifeSpan BioSciences Inc.;
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Apolipoprotein Testing market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Mayo Clinic Laboratories
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories Inc.
- Randox Laboratories Ltd.
- R&D Systems Inc.
- Elabscience Bionovation Inc.
- Sekisui Diagnostics LLC
- RayBiotech Inc.
- Mabtech AB
- Bioss Inc.
- Aviva Systems Biology Corporation
- Abnova Corporation
- DiaSys Diagnostic Systems GmbH
- Enzo Life Sciences Inc.
- Eagle Biosciences Inc.
- CLOUD-CLONE CORP.
- ELK Biotechnology CO. Ltd.
- LifeSpan BioSciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.29 Billion |
| Forecasted Market Value ( USD | $ 4.09 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
